Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul><li>Friday Takeaway—delving a little deeper into UK small caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 30th January 2026 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.</li><li>Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement.</li><li> These companies have global opportunities and are funded for accelerated growth FAB Transformational Platform QUBE Quantum Steps</li></ul>

Friday Takeaway—delving a little deeper into UK small caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 30th January 2026 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement. These companies have global opportunities and are funded for accelerated growth FAB Transformational Platform QUBE Quantum Steps

Fusion Antibodies Ltd - Friday Take Away: 30 January 2026

<ul>
<li>The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll-out.</li>
<li>The Company has completed the computerisation and integration of the entire modular housing production process, creating fully automated, high-precision housing manufacturing platforms.</li>
<li>At the heart of the system is the Company's proprietary Vertical Panel Casting Machine combined with Glass Fibre Reinforced Gypsum wall technology, a blend of advanced materials science, precision automation, and architectural flexibility. </li>
</ul>


The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll-out.
The Company has completed the computerisation and integration of the entire modular housing production process, creating fully automated, high-precision housing manufacturing platforms.
At the heart of the system is the Company's proprietary Vertical Panel Casting Machine combined with Glass Fibre Reinforced Gypsum wall technology, a blend of advanced materials science, precision automation, and architectural flexibility. 


Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025.


Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

<ul>
<li>The alternative energy Company announced further to the Company's announcement dated 20 April 2026 regarding the energisation of the Ghummud site, it has redeployed digital infrastructure originally procured for its 8 Mega Volt Ampere (MVA) development site in the United Arab Emirates to the Ghummud facility, enabling immediate utilisation and accelerated revenue generation.</li>
<li>Once at maximum capacity, the Ghummud site will be capable of generating annualised hosting revenue of $400,000 per MVA per annum.</li>
<li>The Board anticipates this will be achieved within the next six weeks.</li>
</ul>


The alternative energy Company announced further to the Company's announcement dated 20 April 2026 regarding the energisation of the Ghummud site, it has redeployed digital infrastructure originally procured for its 8 Mega Volt Ampere (MVA) development site in the United Arab Emirates to the Ghummud facility, enabling immediate utilisation and accelerated revenue generation.
Once at maximum capacity, the Ghummud site will be capable of generating annualised hosting revenue of $400,000 per MVA per annum.
The Board anticipates this will be achieved within the next six weeks.


<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector.


Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

United Kingdom

Fusion Antibodies Ltd operates as a bio-technology company. The Company develops antibodies for therapeutic drug and diagnostic applications. Fusion Antibodies also renders antibody class switching, stable cell line development, mammalian transient and bacterial protein expression, custom monoclonal antibody production, and sequencing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Fusion Antibodies Ltd - Friday Take Away: 30 January 2026

Friday Takeaway—delving a little deeper into UK small caps This will delve a little deeper on individual companies and focus on...

Hybridan

Hybridan Small Cap Feast: 16/10/2025

The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll...

Hybridan

Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

The Hardman & Co Healthcare Index (HHI) has been running since 2009.Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Hybridan Small Cap Feast: 5 May 2026

Once at maximum capacity, the Ghummud site will be capable of generating annualised hosting revenue of $400,000 per MVA per annum.

Hybridan

Hardman & Co Healthcare Index: 2024 – Tough year for Life Sciences

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)